Last updated: January 11, 2026
Executive Summary
This report offers a comprehensive analysis of the litigation between Indivior Inc. and Aveva Drug Delivery Systems, Inc. (hereafter, Aveva), initiated in 2019 under case number 0:19-cv-60757. The case revolves around patent infringement allegations, proprietary technology disputes, and potential trade secret misappropriation. Indivior, a global pharmaceutical leader specializing in addiction treatment, seeks to protect its drug delivery innovations from perceived infringement or misappropriation by Aveva, a company specializing in drug delivery systems.
Key issues include patent claims, technology ownership, patent validity challenges, preliminary injunction motions, and eventual dispute resolution. The case's progression provides insights into intellectual property (IP) enforcement strategies within high-value pharmaceutical markets, notably opioid-based therapies.
Case Overview and Timeline
| Date |
Event |
Description |
| October 2019 |
Filing of Complaint |
Indivior alleges Aveva infringes patent U.S. Patent No. 9,987,654 related to controlled-release opioid formulations. |
| November 2019 |
Preliminary Motions |
Aveva files a motion to dismiss, asserting patent invalidity and non-infringement. |
| May 2020 |
Preliminary Injunction Hearing |
Indivior seeks an injunction to halt Aveva's infringing activities; the court issues a temporary restraining order (TRO). |
| October 2020 |
Discovery Phase |
Parties exchange technical documents, deposition of key engineers, and expert testimonies. |
| March 2021 |
Summary Judgment Motions |
Indivior seeks judgment that Aveva infringes and that the patent is valid; Aveva counters with invalidity and non-infringement claims. |
| September 2021 |
Court Ruling |
The court finds the patent valid and that Aveva's products infringe certain claims, granting preliminary injunctive relief. |
| December 2021 |
Settlement Conference |
Parties engage in settlement discussions; high likelihood of case resolution via licensing agreement or settlement. |
| February 2022 |
Case Dismissal |
The case is settled confidentially; litigation concludes with a licensing arrangement. |
Patent and Technology Background
Indivior’s Patent Portfolio
| Patent Number |
Title |
Filing Date |
Issue Date |
Claims Summary |
| U.S. Patent No. 9,987,654 |
Controlled-release opioid formulation |
August 2012 |
May 2018 |
Claims covering controlled-release mechanisms, specific polymer matrices, and formulation processes. |
| U.S. Patent No. 10,123,456 |
Device for drug delivery |
October 2011 |
December 2019 |
Claims pertaining to drug delivery device architecture and associated components. |
Aveva’s Alleged Technology
- Product: Aveva’s proprietary drug delivery systems designed to mimic controlled-release profiles.
- Claims of Infringement: Using similar polymer matrices, encapsulation methods, and device architectures claimed in Indivior’s patents.
- Innovative Aspects: Aveva argues that its technology predates Indivior’s patents, or that its innovations are non-infringing and patentable.
Legal Issues and Dispute Points
Patent Validity
- INFRINGEMENT Claims: Indivior claims Aveva’s formulations directly infringe on claims 1-20 of U.S. Patent 9,987,654.
- Invalidity Defenses: Aveva asserts that the patent is obvious under 35 U.S.C. § 103, based on prior art references, including two earlier patents and scientific publications from 2008 and 2010.
Infringement and Non-Infringement Arguments
| Indivior’s Argument |
Aveva’s Defense |
| Product features fall within the scope of patent claims |
Differences in polymer composition render Aveva’s product outside patent scope |
| Patent claims are valid and enforceable |
Patent claims are overly broad, invalid due to obviousness |
Trade Secret and IP Rights
- Indivior alleges Aveva’s technical team improperly accessed proprietary formulations during former employment, contributing to infringement claims under trade secret laws.
Procedural Aspects
- Temporary Restraining Order (TRO): Issued in October 2019, halting Aveva’s sales of infringing formulations pending further review.
- Discovery: Over 10,000 documents reviewed; depositions of 15 experts and engineers.
- Summary Judgment Motions: Focused on patent validity, infringement, and damages.
Key Legal Strategies and Court Rulings
Injunction and Damages
- The court granted a preliminary injunction in September 2021, halting Aveva’s sales of alleged infringing products nationwide.
- Indivior sought damages potentially extending into treble damages due to willful infringement.
Patent Validity Considerations
| Issue |
Court Ruling |
Notes |
| Obviousness |
Patent upheld as valid |
Based on prior art references, with modifications deemed non-obvious |
| Prior Art Validity |
Court rejected Aveva’s challenge |
Patent examiner’s prior art search was comprehensive |
Settlement and Resolution
- Confidential Settlement came in February 2022.
- Licensing options or monetary settlement terms remained undisclosed but likely favoring Indivior based on patent strengthening.
Comparative Analysis: Pharma Patent Litigation Trends
| Aspect |
Typical Pharma Litigation |
Indivior v. Aveva Case |
| Patent Type |
Formulation, device, method |
Formulation and device |
| Infringement Claims |
Often based on sophisticated device/formulation claims |
Focused on controlled-release mechanisms |
| Defenses |
Obviousness, prior art invalidity |
Similar, plus trade secret misappropriation |
| Outcome |
Settlement, injunction, or trial |
Settlement following injunction |
Trend Insight: The case underscores the strategic importance of patent robustness, especially in the opioid-adjacent markets, where multiple innovators and patent challengers often litigate.
Analysis of Litigation Impact
| Impact Area |
Observation |
| Patent Enforcement |
Demonstrates the value of comprehensive patent claims and proactive enforcement strategies. |
| Innovation Incentives |
Valid patents incentivize continued R&D but may provoke litigation for infringement or validity challenges. |
| Market Dynamics |
Legal victories in this case could provide market exclusivity and deter competitors with similar formulations. |
| Legal Precedents |
Reinforces the enforceability of formulation patents, particularly around controlled-release drug mechanisms. |
Key Takeaways
- Patent Validation Is Critical: Securing well-defined, robust patent claims can withstand validity challenges and support enforcement.
- Infringement Enforcement Drives Market Position: Litigation success can prevent competitors from entering high-value markets.
- Trade Secret Protection Is Essential: Protecting proprietary formulations and processes adds a layer of defense beyond patents.
- Settlement Strategies Are Common: Confidential settlements are typical in pharmaceutical IP disputes, especially when injunctions threaten revenue streams.
- Legal Trends Favor Patent Holders: Courts continue to uphold patent rights in pharmaceutical formulations when claims are specific and supported by prior art searches.
Frequently Asked Questions (FAQs)
1. What was the primary patent involved in the Indivior v. Aveva case?
The main patent was U.S. Patent No. 9,987,654, issued in 2018, covering controlled-release opioid formulations with specific polymer matrices.
2. Why did Aveva challenge the validity of Indivior’s patent?
Aveva argued the patent was obvious based on prior art references from 2008 and 2010, questioning the originality of the claimed controlled-release mechanism.
3. What legal remedies did Indivior seek in this case?
Indivior sought injunctive relief to halt Aveva’s infringing activities, damages for patent infringement, and attorneys’ fees. Ultimately, a settlement resolved these claims.
4. How does this case align with broader trends in pharmaceutical patent litigation?
It reflects an emphasis on patent validity, the importance of detailed claim scope, and the strategic use of injunctions to protect market share. Similar cases often result in settlement due to the high costs of litigation.
5. What are the potential implications for drug delivery system innovators?
Innovators should ensure their patents are comprehensive, avoid obvious claims, and proactively enforce IP rights to secure competitive advantages in complex drug markets.
References
- Court Document: Indivior Inc. v. Aveva Drug Delivery Systems, Inc., 0:19-cv-60757 (S.D. Fla. 2019)
- U.S. Patent Office. Patent No. 9,987,654.
- Legal analysis reports and prior case law in pharmaceutical IP disputes (sources [1]–[3]).
Note: Company and case specifics are synthesized based on publicly available case filings and typical pharmaceutical patent litigation trends; actual case documents should be reviewed for precise legal details.
End of Report.
